{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T07:53:55Z","timestamp":1794038035895,"version":"4.8.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,16]]},"abstract":"<jats:p>The efficacy of preoperative chemoradiotherapy (CRT) for anatomically resectable pancreatic adenocarcinoma (R-PDAC) remains contentious. This study aims to elucidate the treatment outcomes of preoperative CRT for R-PDAC and to identify prognostic factors. This retrospective study included 109 R-PDAC patients treated with gemcitabine- or S-1 plus gemcitabine-based preoperative CRT from February 2005 to April 2023. Cox proportional hazards regression was employed to identify factors associated with worse overall survival (OS). Among the 109 cases, 90 patients (82.6%) underwent curative-intent resection following CRT. The median OS for the entire cohort was 36.5 months, significantly longer in resected cases than in unresected cases (40.6 vs 11.4 months). Multivariate analysis identified pretreatment serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) and the Eastern Cooperative Oncology Group performance status \u22651 as independent prognostic factors. When these factors were scored (risk score 0\u20133) using pre-CRT serum CA19-9 level (\u2265640 U\/mL) and CEA (\u22656.1\u2009ng\/mL), OS for risk scores 1 (n\u2005=\u200541), 2 (n\u2005=\u200520) or 3 (n\u2005=\u20056) was significantly shorter than for risk score 0 (n\u2005=\u200542) (score 0 vs 1 vs 2 vs 3: 49.1 vs 33.8 vs 16.1 vs 16.8 months). The presence of portal vein invasion on imaging and post-CRT serum CA 19-9 level (\u2265111 U\/mL) were independent prognostic factors in resected cases. Biological factors, including serum levels of CA19-9 and CEA, along with conditional factor of Eastern Cooperative Oncology Group performance status \u22651, were identified as independent prognostic factors for R-PDAC patients treated with preoperative CRT. Preoperative CRT is considered effective for cases lacking these risk factors.<\/jats:p>","DOI":"10.1097\/md.0000000000042441","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T14:00:57Z","timestamp":1747836057000},"page":"e42441","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Prognostic impacts of biological and conditional factors in patients with anatomically resectable pancreatic adenocarcinoma treated with preoperative chemoradiotherapy"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5997-4342","authenticated-orcid":false,"given":"Yasuhiro","family":"Murata","sequence":"first","affiliation":[{"name":"Department of the Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shugo","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Department of the Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kishiwada","sequence":"additional","affiliation":[{"name":"Department of the Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoi","family":"Hayasaki","sequence":"additional","affiliation":[{"name":"Department of the Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motonori","family":"Nagata","sequence":"additional","affiliation":[{"name":"Department of the Radiology, Mie University Graduate School of Medicine, Tsu, Mie, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Noguchi","sequence":"additional","affiliation":[{"name":"Department of the Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Gyoten","sequence":"additional","affiliation":[{"name":"Department of the Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of the Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of the Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Iizawa","sequence":"additional","affiliation":[{"name":"Department of the Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tanemura","sequence":"additional","affiliation":[{"name":"Department of the Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohisa","family":"Kuriyama","sequence":"additional","affiliation":[{"name":"Department of the Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260811","doi-asserted-by":"crossref","first-page":"2129884","DOI":"10.1080\/08941939.2022.2129884","article-title":"Pancreatic cancer: A review of current treatment and novel therapies.","volume":"36","author":"Kolbeinsson","year":"2023","journal-title":"J Invest Surg"},{"key":"R2-20260811","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41571-023-00746-1","article-title":"Neoadjuvant therapy for pancreatic cancer.","volume":"20","author":"Springfeld","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"R3-20260811","doi-asserted-by":"crossref","first-page":"28","DOI":"10.14701\/ahbps.22-052","article-title":"Neoadjuvant chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: Meta-analysis and trial sequential analysis of randomized controlled trials.","volume":"27","author":"Hajibandeh","year":"2023","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"key":"R4-20260811","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","article-title":"Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2\/3 trial.","volume":"268","author":"Jang","year":"2018","journal-title":"Ann Surg"},{"key":"R5-20260811","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the dutch randomized PREOPANC trial.","volume":"40","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"key":"R6-20260811","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00535-016-1217-x","article-title":"Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.","volume":"52","author":"Fujii","year":"2017","journal-title":"J Gastroenterol"},{"key":"R7-20260811","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00423-015-1304-0","article-title":"Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer.","volume":"400","author":"Sho","year":"2015","journal-title":"Langenbecks Arch Surg"},{"key":"R8-20260811","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1245\/s10434-025-16956-z","article-title":"Neoadjuvant chemoradiotherapy using moderately hypofractionated intensity-modulated radiotherapy versus upfront surgery for resectable pancreatic cancer: a retrospective cohort study.","volume":"32","author":"Yamane","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"R9-20260811","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/MPA.0b013e3182236442","article-title":"Impact of histological response after neoadjuvant chemoradiotherapy on recurrence-free survival in UICC-T3 pancreatic adenocarcinoma but not in UICC-T4.","volume":"41","author":"Murata","year":"2012","journal-title":"Pancreas"},{"key":"R10-20260811","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.pan.2021.08.011","article-title":"Clinical significance and predictors of complete or near-complete histological response to preoperative chemoradiotherapy in patients with localized pancreatic ductal adenocarcinoma.","volume":"21","author":"Murata","year":"2021","journal-title":"Pancreatology"},{"key":"R11-20260811","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.3390\/cancers15184627","article-title":"Neo-adjuvant treatment in primary resectable pancreatic cancer: a systematic review and PRISMA-compliant updated metanalysis of oncological outcomes.","volume":"15","author":"Roesel","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R12-20260811","article-title":"Pancreatic adenocarcinoma (Version 2.2024)"},{"key":"R13-20260811","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"key":"R14-20260811","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.hpb.2019.01.012","article-title":"Biological and conditional factors should be included when defining criteria for resectability for patients with pancreatic cancer.","volume":"21","author":"Kato","year":"2019","journal-title":"HPB (Oxford)"},{"key":"R15-20260811","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1245\/s10434-022-13043-5","article-title":"Validation of the anatomical and biological definitions of borderline resectable pancreatic cancer according to the 2017 international consensus for survival and recurrence in patients with pancreatic ductal adenocarcinoma undergoing upfront surgery.","volume":"30","author":"Lee","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"R16-20260811","doi-asserted-by":"crossref","first-page":"4956","DOI":"10.1245\/s10434-024-15070-w","article-title":"The value of biological and conditional factors for staging of patients with resectable pancreatic cancer undergoing upfront resection: a nationwide analysis.","volume":"31","author":"Schouten","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"R17-20260811","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.21037\/tcr-22-1258","article-title":"Is it justified to assess the resectability of pancreatic cancer combined with biological and conditional factors?","volume":"11","author":"Huang","year":"2022","journal-title":"Transl Cancer Res"},{"key":"R18-20260811","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","article-title":"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017.","volume":"18","author":"Isaji","year":"2018","journal-title":"Pancreatology"},{"key":"R21-20260811","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/MPA.0000000000001227","article-title":"Comparative study between gemcitabine-based and gemcitabine plus S1-based preoperative chemoradiotherapy for localized pancreatic ductal adenocarcinoma, with special attention to initially locally advanced unresectable tumor.","volume":"48","author":"Takeuchi","year":"2019","journal-title":"Pancreas"},{"key":"R22-20260811","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1007\/s00268-011-0984-z","article-title":"Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma.","volume":"35","author":"Garcea","year":"2011","journal-title":"World J Surg"},{"key":"R23-20260811","first-page":"1001","article-title":"Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients.","volume":"85","author":"Onodera","year":"1984","journal-title":"Nihon Geka Gakkai Zasshi"},{"key":"R24-20260811","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group.","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"R25-20260811","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s11605-014-2495-3","article-title":"Anterior approach to the superior mesenteric artery by using nerve plexus hanging maneuver for borderline resectable pancreatic head carcinoma.","volume":"18","author":"Mizuno","year":"2014","journal-title":"J Gastrointest Surg"},{"key":"R26-20260811","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"R27-20260811","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.ijsu.2013.10.005","article-title":"Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.","volume":"11","author":"Distler","year":"2013","journal-title":"Int J Surg"},{"key":"R28-20260811","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2147\/OTT.S116136","article-title":"Combination of preoperative CEA and CA19-9 improves prediction outcomes in patients with resectable pancreatic adenocarcinoma: results from a large follow-up cohort.","volume":"10","author":"Zhou","year":"2017","journal-title":"Onco Targets Ther"},{"key":"R29-20260811","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00534-006-1184-3","article-title":"Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.","volume":"14","author":"Fujioka","year":"2007","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"R30-20260811","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1111\/j.1440-1746.2009.05935.x","article-title":"Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?","volume":"24","author":"Kim","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"R31-20260811","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/00006676-199411000-00011","article-title":"Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic cancer.","volume":"9","author":"Yasue","year":"1994","journal-title":"Pancreas"},{"key":"R32-20260811","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/1354750X.2020.1725786","article-title":"Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis.","volume":"25","author":"van Manen","year":"2020","journal-title":"Biomarkers"},{"key":"R33-20260811","doi-asserted-by":"crossref","first-page":"13223","DOI":"10.1016\/S0021-9258(18)43031-1","article-title":"Monoclonal antibodies directed against the human Leb blood group antigen.","volume":"256","author":"Brockhaus","year":"1981","journal-title":"J Biol Chem"},{"key":"R34-20260811","first-page":"5501","article-title":"Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.","volume":"47","author":"Tempero","year":"1987","journal-title":"Cancer Res"},{"key":"R35-20260811","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/SLA.0000000000001741","article-title":"Potential biomarkers in lewis negative patients with pancreatic cancer.","volume":"265","author":"Luo","year":"2017","journal-title":"Ann Surg"},{"key":"R36-20260811","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/SLA.0000000000003284","article-title":"Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline\/locally advanced pancreatic cancer.","volume":"273","author":"Truty","year":"2021","journal-title":"Ann Surg"},{"key":"R37-20260811","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s10147-012-0474-9","article-title":"Performance status of patients is the major prognostic factor at all stages of pancreatic cancer.","volume":"18","author":"Tas","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"R38-20260811","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3390\/cancers11040514","article-title":"Prognostic nutritional index after chemoradiotherapy was the strongest prognostic predictor among biological and conditional factors in localized pancreatic ductal adenocarcinoma patients.","volume":"11","author":"Ichikawa","year":"2019","journal-title":"Cancers (Basel)"},{"key":"R39-20260811","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.pan.2015.04.004","article-title":"Host systemic inflammatory response influences outcome in pancreatic cancer.","volume":"15","author":"Imrie","year":"2015","journal-title":"Pancreatology"},{"key":"R40-20260811","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12885-019-5460-4","article-title":"Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients.","volume":"19","author":"Aoki","year":"2019","journal-title":"BMC Cancer"},{"key":"R41-20260811","doi-asserted-by":"crossref","first-page":"e0264573","DOI":"10.1371\/journal.pone.0264573","article-title":"Predictive risk factors for early recurrence in patients with localized pancreatic ductal adenocarcinoma who underwent curative-intent resection after preoperative chemoradiotherapy.","volume":"17","author":"Murata","year":"2022","journal-title":"PLoS One"},{"key":"R42-20260811","doi-asserted-by":"crossref","first-page":"101998","DOI":"10.1016\/j.suronc.2023.101998","article-title":"Superior mesenteric vein\/portal vein contact in preoperative imaging indicates biological malignancy in anatomically resectable pancreatic cancer.","volume":"51","author":"Shirai","year":"2023","journal-title":"Surg Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042441","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:00:49Z","timestamp":1786435249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":40,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042441","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]}}}